Literature DB >> 24317448

BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.

A Morotti1, C Panuzzo2, S Crivellaro2, B Pergolizzi3, U Familiari4, A H Berger5, G Saglio2, P P Pandolfi5.   

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor phosphatase and tensin homolog (PTEN) has recently been shown to have a critical role in the pathogenesis of CML. Nuclear localization and proper nuclear-cytoplasmic shuttling are crucial for PTEN's tumor suppressive function. In this study, we show that BCR-ABL enhances HAUSP-induced de-ubiquitination of PTEN in turn favoring its nuclear exclusion. We further demonstrate that BCR-ABL physically interacts with and phosphorylates HAUSP on tyrosine residues to trigger its activity. Importantly, we also find that PTEN delocalization induced by BCR-ABL does not occur in the leukemic stem cell compartment due to high levels of PML, a potent inhibitor of HAUSP activity toward PTEN. We therefore identify a new proto-oncogenic mechanism whereby BCR-ABL antagonizes the nuclear function of the PTEN tumor suppressor, with important therapeutic implications for the eradication of CML minimal residual disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24317448     DOI: 10.1038/leu.2013.370

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

1.  BCR-ABL kinase is dead; long live the CML stem cell.

Authors:  Alexander Perl; Martin Carroll
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

Review 2.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

3.  Ubiquitination regulates PTEN nuclear import and tumor suppression.

Authors:  Lloyd C Trotman; Xinjiang Wang; Andrea Alimonti; Zhenbang Chen; Julie Teruya-Feldstein; Haijuan Yang; Nikola P Pavletich; Brett S Carver; Carlos Cordon-Cardo; Hediye Erdjument-Bromage; Paul Tempst; Sung-Gil Chi; Hyo-Jong Kim; Tom Misteli; Xuejun Jiang; Pier Paolo Pandolfi
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

4.  Essential role for nuclear PTEN in maintaining chromosomal integrity.

Authors:  Wen Hong Shen; Adayabalam S Balajee; Jianli Wang; Hong Wu; Charis Eng; Pier Paolo Pandolfi; Yuxin Yin
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

5.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

6.  Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Authors:  Min Sup Song; Arkaitz Carracedo; Leonardo Salmena; Su Jung Song; Ainara Egia; Marcos Malumbres; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-01-21       Impact factor: 41.582

7.  PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

Authors:  Cong Peng; Yaoyu Chen; Zhongfa Yang; Haojian Zhang; Lori Osterby; Alan G Rosmarin; Shaoguang Li
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

8.  PML targeting eradicates quiescent leukaemia-initiating cells.

Authors:  Keisuke Ito; Rosa Bernardi; Alessandro Morotti; Sahoko Matsuoka; Giuseppe Saglio; Yasuo Ikeda; Jacalyn Rosenblatt; David E Avigan; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2008-05-11       Impact factor: 49.962

Review 9.  Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation.

Authors:  Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

10.  The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.

Authors:  Min Sup Song; Leonardo Salmena; Arkaitz Carracedo; Ainara Egia; Francesco Lo-Coco; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2008-08-20       Impact factor: 49.962

View more
  34 in total

Review 1.  USP7: Structure, substrate specificity, and inhibition.

Authors:  Alexandra Pozhidaeva; Irina Bezsonova
Journal:  DNA Repair (Amst)       Date:  2019-02-16

2.  Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro.

Authors:  Bo Jing; Meng Liu; Li Yang; Hai-Yan Cai; Jie-Bo Chen; Ze-Xi Li; Xi Kou; Yun-Zhao Wu; Dong-Jun Qin; Li Zhou; Jin Jin; Hu Lei; Han-Zhang Xu; Wei-Wei Wang; Ying-Li Wu
Journal:  Acta Pharmacol Sin       Date:  2017-11-23       Impact factor: 6.150

3.  BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Authors:  Alessandro Morotti; Cristina Panuzzo; Sabrina Crivellaro; Giovanna Carrà; Carmen Fava; Angelo Guerrasio; Pier Paolo Pandolfi; Giuseppe Saglio
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1.

Authors:  Ming Gao; Zijuan Qi; Min Deng; Hongyang Huang; Zhijie Xu; Guijie Guo; Jiajun Jing; Xiaofeng Huang; Ming Xu; Jake A Kloeber; Sijin Liu; Jinzhou Huang; Zhenkun Lou; Jinxiang Han
Journal:  Oncogene       Date:  2022-07-11       Impact factor: 8.756

Review 5.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

Review 6.  Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease.

Authors:  Radhika Rawat; Daniel T Starczynowski; Panagiotis Ntziachristos
Journal:  Curr Opin Cell Biol       Date:  2019-03-18       Impact factor: 8.382

Review 7.  PTEN Nuclear Functions.

Authors:  Jason Ho; Edward S Cruise; Ryan J O Dowling; Vuk Stambolic
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

Review 8.  Deubiquitinases and the new therapeutic opportunities offered to cancer.

Authors:  Roland Pfoh; Ira Kay Lacdao; Vivian Saridakis
Journal:  Endocr Relat Cancer       Date:  2015-02       Impact factor: 5.678

9.  Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.

Authors:  Simona Taverna; Marco Giallombardo; Marzia Pucci; Anna Flugy; Mauro Manno; Samuele Raccosta; Christian Rolfo; Giacomo De Leo; Riccardo Alessandro
Journal:  Oncotarget       Date:  2015-09-08

10.  BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.

Authors:  Cristina Panuzzo; Sabrina Crivellaro; Giovanna Carrà; Angelo Guerrasio; Giuseppe Saglio; Alessandro Morotti
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.